International Journal of Research in Pharmacy and Pharmaceutical Sciences
www.pharmacyjournal.in
ISSN: 2455-698X
Received: 20-01-2026, Accepted: 19-02-2026, Published: 06-03-2026
Volume 11, Issue 1, 2026, Page No. 146-149

A review article on Quality by Design (QBD): Advanced regulatory framework, industrial implementation, and emerging applications in medicinal plant research

K Shruthi*, G Pranay Teja, Dr. Ramya Sree
Department of Pharmaceutical Analysis, Sri Venkateshwara College of Pharmacy, Madhapur, Hyderabad, Telangana, India
Corressponding Author: K Shruthi

Abstract
Quality by Design (QbD) represents a paradigm shift from empirical, end-product testing toward a science- and risk-based framework that systematically embeds quality into product and process development. Initially institutionalized within pharmaceutical regulatory frameworks through ICH Q8 (R2), Q9, and Q10 guidelines, QbD has evolved into a comprehensive lifecycle management strategy encompassing product development, process optimization, control strategy establishment, and continuous improvement. This review critically evaluates the conceptual evolution, regulatory foundations, mechanistic components, and industrial applications of QbD. Particular emphasis is placed on its expanding role in herbal drug development and medicinal plant standardization, where intrinsic biological variability poses significant quality challenges. The integration of multivariate statistical tools, design of experiments (DoE), process analytical technology (PAT), and chemometric profiling has enabled the translation of QbD principles into phytopharmaceutical research. Despite demonstrable advantages—including enhanced regulatory flexibility, reduced batch failures, and improved process robustness—barriers such as data complexity, high implementation cost, and lack of global harmonization remain. Emerging digital technologies including artificial intelligence, digital twins, and blockchain systems are poised to augment QbD-based predictive control models. This manuscript provides a critical synthesis of current evidence and identifies future research directions necessary for strengthening QbD implementation across synthetic and plant- based medicinal products.

Keywords: Quality by Design (QBD), ICH Guidelines, Design of Experiments (DOE), Process Analytical Technology (PAT), herbal drug development, medicinal plant, standardization, chemometrics, phytopharmaceuticals

Introduction

The concept of quality within pharmaceutical sciences has undergone a profound transformation over the past three decades. Historically, quality assurance relied predominantly on retrospective evaluation through end-product testing. Such approaches, while compliant with Good Manufacturing Practices (GMP), often failed to prevent variability arising from complex raw material attributes and process fluctuations. This reactive paradigm was increasingly challenged by regulatory agencies seeking more robust, science-driven development frameworks.

Quality by Design (QbD) emerged as a systematic alternative, fundamentally redefining quality as a property that must be proactively engineered into a product rather than inspected post-manufacture. According to ICH Q8 (R2), QbD is defined as "a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management." This definition underscores three foundational pillars: predefined quality objectives, mechanistic process understanding, and risk-based control.

While initially conceptualized for synthetic pharmaceutical products, the QbD framework has demonstrated increasing relevance in biologics, nanomedicine, advanced drug delivery systems, and, more recently, phytopharmaceuticals and medicinal plant-based formulations. Herbal products present unique challenges due to raw material heterogeneity, geographical variability, phytochemical complexity, and seasonal influences. Consequently, the application of QbD in medicinal plant research represents both a scientific necessity and a regulatory imperative.

This review critically examines the theoretical underpinnings, regulatory evolution, industrial implementation, and emerging interdisciplinary applications of QbD, with particular emphasis on medicinal plant standardization.

Regulatory and Conceptual Evolution of QbD

The regulatory genesis of QbD can be traced to the FDA's "Pharmaceutical cGMPs for the 21st Century" initiative (2002), which advocated modernization of manufacturing through innovation and risk-based decision-making. This initiative catalyzed the formalization of QbD within the ICH framework.

ICH Q8 introduced the concept of pharmaceutical development based on systematic experimentation and design space establishment. ICH Q9 provided structured methodologies for Quality Risk Management (QRM), while ICH Q10 established a comprehensive Pharmaceutical Quality System (PQS) integrating lifecycle management and continuous improvement.

Subsequent expansions into ICH Q11 (drug substances) and ICH Q12 (post-approval lifecycle management) reinforced regulatory flexibility when scientific understanding and design space justification are adequately demonstrated.

Collectively, these guidelines shifted regulatory evaluation from document- centric compliance toward science-centric assessment.

Key aspects

Quality by Design (QbD) is a holistic approach to product development that integrates quality into every stage of the lifecycle, from conceptualization to commercialization. Unlike traditional quality control methods, which rely on

end-stage testing, QbD employs risk-based strategies to preempt defects.



Fundamental Components of the QbD Framework

1. Quality Target Product Profile (QTPP)

The QTPP serves as a strategic blueprint outlining the intended therapeutic performance, safety profile, route of administration, dosage form, and stability parameters. It establishes the translational bridge between clinical objectives and manufacturing design.

2. Critical Quality Attributes (CQAs)

CQAs are quantifiable physicochemical, biological, or microbiological characteristics that directly impact safety and efficacy. Their identification requires mechanistic understanding supported by risk assessment and statistical correlation with clinical outcomes.

3. Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs)

CMAs refer to intrinsic properties of raw materials that influence CQAs, whereas CPPs represent operational variables whose variability can impact product quality. Multivariate Design of Experiments (DoE) methodologies are commonly employed to elucidate parameter interactions.

4. Design Space and Control Strategy

The design space represents a multidimensional region within which process variability does not compromise product quality. Regulatory agencies permit operational flexibility within this space without necessitating prior approval, thereby incentivizing scientific rigor during development.

Design of Experiments and Design Space

Design of Experiments (DOE) is an essential statistical tool used in QbD to study the relationships between multiple variables and their effects on product quality. DOE enables systematic experimentation by simultaneously evaluating several factors and identifying interactions among them. This approach helps optimize formulation and process conditions while reducing the number of experimental trials required. The concept of design space is closely related to DOE and represents the multidimensional range of process parameters within which product quality is assured. Operating within the established design space provides flexibility in manufacturing and reduces the need for regulatory approvals when minor adjustments are made. Establishing a well-defined design space is a key objective of QbD implementation.

Analytical Quality by Design (AQbD)

Analytical Quality by Design extends QbD principles to analytical method development. AQbD focuses on designing robust analytical procedures that consistently produce accurate and reliable results. The process begins with defining the Analytical Target Profile (ATP), which specifies the desired performance characteristics of an analytical method. Similar to product development, AQbD involves identifying critical method parameters, performing risk assessment, and optimizing conditions using statistical tools. This approach ensures method robustness, reduces variability, and improves regulatory compliance. The control strategy integrates in-process monitoring, PAT tools, statistical process control (SPC), and real-time release testing (RTRT) to ensure sustained process robustness.

QbD in Synthetic and Biotechnological Products

In conventional pharmaceutical formulations, QbD has optimized tablet compression parameters, dissolution profiles, and excipient interactions. In biologics manufacturing, it has facilitated control over cell culture conditions, glycosylation patterns, and aggregation phenomena. The incorporation of PAT tools such as near-infrared spectroscopy (NIR), Raman spectroscopy, and chemometric modeling has significantly enhanced real-time monitoring capabilities, reducing variability and improving yield efficiency.

Quality by Design in Medicinal Plants and Herbal Drug Development

1. Challenges in Herbal Drug Standardization

Medicinal plants are intrinsically heterogeneous systems influenced by genotype, soil composition, climate, harvesting time, and post-harvest processing. Unlike synthetic drugs with defined molecular structures, herbal formulations often contain complex phytochemical matrices

comprising alkaloids, flavonoids, terpenoids, phenolics, and glycosides. Traditional quality control approaches relying solely on marker compound estimation are insufficient to capture holistic phytochemical variability. Consequently, variability in bioactive concentration can compromise safety, efficacy, and reproducibility.



2. QbD Principles in Phytopharmaceutical Research

The integration of QbD into medicinal plant research enables systematic identification of:

- **Quality Target Product Profile (QTPP):** Defined in terms of therapeutic indication, dosage form (e.g., extract, tablet, capsule), bioactive consistency, and stability.
- **Critical Quality Attributes (CQAs):** Total phenolic content, marker compound concentration, antioxidant capacity, microbial load, moisture content, and dissolution behavior.
- **Critical Material Attributes (CMAs):** Plant part used, geographical origin, harvest season, drying method, and extraction solvent.
- **Critical Process Parameters (CPPs):** Extraction temperature, solvent- to-drug ratio, maceration time, pH, and drying conditions.

3. Tools in Herbal Qbd

Chemometrics and PAT in Herbal QbD

Advanced analytical platforms such as HPLC, LC-MS/MS, GC-MS, and NMR, coupled with chemometric tools (PCA, PLS regression), enable fingerprint profiling of complex herbal extracts. These approaches align with QbD objectives by establishing comprehensive chemical fingerprints rather than relying on single-marker quantification. Process Analytical Technology (PAT) tools provide real-time monitoring of extraction kinetics and moisture levels, enhancing reproducibility in large-scale phytopharmaceutical manufacturing. Design of Experiments (DoE) facilitates optimization of extraction processes to maximize bioactive yield while minimizing degradation. Response Surface Methodology (RSM) is frequently applied to evaluate interactions between solvent concentration and extraction temperature.

4. Regulatory Implications

Regulatory frameworks for herbal medicines vary globally; however, the implementation of QbD can harmonize quality standards by providing robust scientific justification for process control. The concept of "design space" is particularly valuable in managing variability inherent in plant-derived materials.

Benefits and Strategic Advantages

Implementation of QbD in medicinal plant research ensures batch-to-batch consistency, improves stability profiles, reduces contamination risks, and strengthens regulatory submissions. It enhances credibility of herbal products in global markets by aligning them with pharmaceutical-grade quality standards.

Limitations and Implementation Barriers

Despite its promise, QbD application in phytopharmaceuticals faces several barriers, including limited availability of standardized reference materials, high analytical costs, and insufficient interdisciplinary expertise. Furthermore, variability in traditional harvesting practices may limit reproducibility.

Future Perspectives: Digital and Sustainable QbD

The convergence of QbD with artificial intelligence and machine learning offers predictive modeling of phytochemical variability based on environmental data. Digital twin technology may simulate extraction processes, reducing experimental burden. Blockchain-enabled traceability can enhance supply chain transparency for medicinal plants, addressing issues of adulteration and sustainability. Integration of green chemistry principles within QbD frameworks can promote eco-friendly extraction methodologies, aligning quality assurance with environmental stewardship.

Conclusion

Quality by Design represents a transformative, lifecycle-oriented framework that transcends traditional pharmaceutical boundaries. Its systematic integration into medicinal plant research addresses longstanding challenges of variability, reproducibility, and regulatory compliance. By combining multivariate statistical tools, advanced analytical platforms, and digital technologies, QbD has the potential to elevate phytopharmaceuticals to globally

harmonized quality standards. Continued interdisciplinary research and regulatory collaboration will be essential for fully realizing this paradigm across synthetic and plant-based medicinal products.

References

1. International Council for Harmonisation (ICH). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. Geneva: ICH, 2009.
2. International Council for Harmonisation (ICH). ICH Q9: Quality Risk Management. Geneva: ICH, 2005.
3. International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System. Geneva: ICH, 2008.
4. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to get there. International Journal of Pharmaceutics,2017:528(1-2):354- 359.
5. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nature Biotechnology,2009:27(1):26-34.
6. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: Concepts for ANDAs. AAPS Journal,2008:10(2):268-276.
7. Woodcock J, Yu LX. Quality by design and pharmaceutical manufacturing. Annual Review of Chemical and Biomolecular Engineering,2014:5:1-23.
8. Peraman R, Bhadraya K, Padmanabha RY. Analytical quality by design: A tool for regulatory flexibility and robust analytics. International Journal of Analytical Chemistry,2015:2015:868727.
9. Rozet E, Lebrun P, Debrus B, Boulanger B, Hubert P. Design space for analytical methods. Trends in Analytical Chemistry,2013:42:157-167.
10. Beg S, Sandhu PS, Batra RS, Khurana RK, Singh B. QbD-based systematic development of herbal formulations: An emerging trend. Phytomedicine,2019:64:152903.
11. Monteiro SS, *et al*. Application of QbD approach in herbal extract development. Industrial Crops and Products,2020:150:112386.
12. Gad HA, El-Ahmady SH, Abou-Shoer MI, Al-Azizi MM. Application of chemometrics in authentication and quality control of herbal medicines: A review. Phytochemical Analysis,2021:32(4):403-419.